Taken together, these findings suggest a new role for NIPBL, different from that of RAD21, in the regulation of RUNX1 expression and that aberrant expression of NIPBL, such as in AML patients with NPM+ mutation, might lead to alteration in RUNX1 transcript levels. The gene discussed is RUNX1; the disease is acute myeloid leukemia.